ERBB2 and breast carcinoma: in the New England Journal of Medicine reported the results of the NSABP B-31 study, which showed that after a regimen of doxorubicin and cyclophosphamide, adding trastuzumab to paclitaxel reduced recurrence by 50% among women with HER2-positive breast cancer and reduced distant recurrence by 8.8% at 3 years (18).